EU Approves Gilead’s New HIV Prevention Drug
The European Commission has approved Gilead’s lenacapavir, a twice-yearly HIV prevention injection, offering high-risk individuals a long-acting alternative and expanding access across Europe and low-income countries. The European Commission has granted marketing authorization for Gilead Sciences’ lenacapavir, a twice-yearly injection aimed at preventing HIV infection. Branded as Yeytuo in Europe, the drug is intended for […]
The post EU Approves Gilead’s New HIV Prevention Drug appeared first on Khaama Press.